U.S. Entertainment Stock News

In late February 2026, Marriott Vacations Worldwide reported fourth-quarter and full-year 2025 results showing revenue of US$1.32 billion for the quarter and US$5.03 billion for the year, alongside non-cash impairment charges of US$546 million that drove a net loss and sharply reduced earnings per share. At the same time, the company appointed long-time industry executives Matt Avril as CEO and Mike Flaskey as President, issued 2026 guidance pointing to higher contract sales and adjusted...

Rubrik (NYSE:RBRK) is drawing fresh attention as recent updates highlight strong revenue gains, high net retention, and solid margins. The company reports operating with a very low share of its target market, which points to meaningful room for further enterprise cybersecurity adoption. Management continues to emphasize Rubrik’s subscription-based model and high switching costs as key supports for its position in data security. At a share price of $51.96, NYSE:RBRK sits against a backdrop...

Lennox International recently reported its fourth-quarter 2025 results, with both earnings per share and revenue coming in below analyst forecasts, while director Shane D. Wall sold 100 shares of common stock on February 25, 2026. This combination of an earnings shortfall and insider selling has sharpened investor focus on how resilient Lennox’s longer-term HVAC growth story may be. We’ll now examine how the weaker-than-expected quarterly earnings could influence Lennox’s previously outlined...

SkyWater Technology, Inc. reported past fourth-quarter 2025 sales of US$171.04 million versus US$75.49 million a year earlier, with a quarterly net loss of US$7.78 million, while full-year 2025 sales reached US$442.14 million and net income was US$118.92 million, reversing the prior year’s loss. Alongside these results, the company is sharpening its focus on growth and customer acquisition, appointing veteran semiconductor executive Christine Dunbar to lead sales and solutions engineering as...

What triggered the latest Wells Fargo move? Wells Fargo (WFC) shares dropped 6.6% after investors reacted to the bank’s reported exposure to Market Financial Solutions Ltd., a collapsed UK mortgage firm, alongside fresh concerns about inflation and broader credit risk. The sharp move has pushed the stock lower over the month and year to date. This has prompted many shareholders to reassess how this credit headline, together with rising macro worries, fits with the bank’s current valuation and...

Sysco has launched a new pilot program, Home Grown by Sysco, to expand locally sourced food offerings across select regions in North America. The company has also signed a nationwide distribution partnership with Reborn Coffee to support the coffee brand's franchise expansion across the United States. For investors watching NYSE:SYY, these moves come as Sysco trades around $91.16 per share, with returns of 25.5% year to date and 23.8% over the past year. The stock has also returned 29.6%...

In late February 2026, Intellia Therapeutics filed a US$26.84 million shelf registration for 2,000,000 common shares tied to its employee stock ownership plan, alongside reporting Q4 2025 results that exceeded earnings and revenue expectations. These updates, combined with the FDA lifting a clinical hold on the MAGNITUDE-2 trial and rapid Phase 3 enrollment for lonvo-z, underline how Intellia is progressing simultaneously on clinical, regulatory, and workforce-focused fronts. We’ll now...

Coca-Cola (KO) just approved its 64th consecutive annual dividend increase, lifting the quarterly payout by about 4% to $0.53 per share. This move directly targets income focused investors. See our latest analysis for Coca-Cola. At a share price of $81.56, Coca-Cola’s recent 30-day share price return of 9.02% and year to date gain of 18.00% suggest building momentum. The 5-year total shareholder return of 83.58% points to solid longer term compounding alongside the latest dividend increase...

If you are wondering whether Upwork's recent share price swings have created an opportunity or a value trap, looking closely at what the market is actually pricing in can help frame your next move. Upwork's shares last closed at US$13.42, with a 7 day return of 7.3%, a 30 day return of a 33.0% decline, a year to date return of a 32.4% decline, a 1 year return of an 8.8% decline, a 3 year return of 12.5% and a 5 year return of a 68.2% decline. Recent attention on Upwork has centered on how...

If you are wondering whether Day One Biopharmaceuticals' current share price lines up with its underlying worth, you are not alone. The stock most recently closed at US$10.60, with a 7 day return of 10% decline, a 30 day return of 5% decline, gains of 19.8% year to date and 17% over the past year, while the 3 year return sits at 43.4% decline. Recent news around Day One has largely focused on its development stage oncology pipeline and ongoing progress in clinical programs, which can...

Ameren Corporation recently completed several fixed‑income transactions, including a US$399.21 million offering of 5% senior notes due 2036, alongside earlier first mortgage bond issuances by Ameren Missouri to refinance short‑term debt and support grid investments. Together, these bond deals reshape Ameren’s funding mix by locking in long‑term, fixed‑rate capital and reducing refinancing uncertainty around its large infrastructure program. Next, we’ll explore how Ameren’s shift toward...

Westlake Corporation has reported weaker results for the fourth quarter and full year 2025, with sales falling to US$2,533 million and a quarterly net loss of US$544 million, alongside the planned retirement of long-serving Chief Financial Officer M. Steven Bender and the appointment of Bhavesh V. “Bob” Patel and CEO Jean-Marc Gilson to an expanded Board. Despite these earnings pressures and leadership changes, the Board’s decision to maintain a regular US$0.53 per-share dividend and the...

Edwards Lifesciences recently secured U.S. FDA approval for its SAPIEN M3 transcatheter mitral valve replacement system, issued 2026 sales guidance, and saw an FTC injunction block its planned JenaValve acquisition, while an EU antitrust investigation into its policies concluded. These developments collectively reduce legal uncertainty, highlight Edwards’ innovation in structural heart therapies, and align with its goal to broaden global access to cardiovascular treatments by 2030. We’ll now...

What the latest earnings tell you about Diversified Healthcare Trust Diversified Healthcare Trust (DHC) has just reported fourth quarter and full year 2025 results, showing lower quarterly sales but a narrower net loss, a combination that naturally puts the stock back on investors’ radar. See our latest analysis for Diversified Healthcare Trust. That earnings update landed after a strong run in the shares, with a 90 day share price return of 39.96% and a year to date share price return of...

Mercury Systems (MRCY) recently reported year over year growth in bookings, revenue, adjusted EBITDA, and backlog, supported by faster customer deliveries and factory automation investments, and outlined new opportunities linked to the defense budget. See our latest analysis for Mercury Systems. At a share price of US$89.03, Mercury Systems has seen a 33.28% 90 day share price return and a very large 100.47% 1 year total shareholder return, suggesting recent momentum has been strong as...

MannKind (MNKD) is back in focus after partner United Therapeutics introduced a soft mist inhaler designed to compete with Tyvaso DPI, raising fresh questions around MannKind’s future royalty stream and overall risk profile. See our latest analysis for MannKind. The stock’s 7 day share price return of 40.79% and 30 day share price return of 43.25% follow earnings that paired higher revenue with a quarterly loss, while the United Therapeutics soft mist inhaler news sharply reset sentiment...

Vera Therapeutics (VERA) is back in focus after the FDA granted priority review to its lead drug candidate, atacicept, following positive Phase 3 IgA nephropathy data and company updates on funding and launch readiness. See our latest analysis for Vera Therapeutics. Despite the FDA priority review and Phase 3 success for atacicept, Vera Therapeutics’ recent share price returns have cooled, with a 30 day share price return decline of 5.71% and a year to date share price return decline of...

In late February 2026, Pinnacle Financial Partners was highlighted by hedge funds as one of the ten leading banking stocks, with analysts citing stronger capital levels and higher earnings forecasts following its fourth-quarter results and management’s confident outlook. A few days later, hotter-than-expected inflation data and rising worries about credit risk in areas like private credit and leveraged loans led investors to reassess regional banks’ risk profiles, putting pressure on...

Shift4 Payments (FOUR) is back in focus after a sharp post earnings sell off, weaker forward guidance, and the resignation of Executive Chairman Jared Isaacman. Shares have slid to multi year lows despite ongoing international expansion. See our latest analysis for Shift4 Payments. The weak outlook and leadership change have come on top of a sharp reset in expectations, with a 1 day share price return of 9.0% decline and a 1 year total shareholder return of 55.4% decline, pointing to fading...

Sterling Infrastructure, Inc. has already reported its fourth-quarter and full-year 2025 results, with Q4 sales of US$755.61 million versus US$498.83 million a year earlier, and full-year 2025 sales of US$2.49 billion and net income of US$290.15 million. Alongside these results, management issued 2026 guidance calling for US$3.05–3.20 billion in revenue and US$11.65–12.25 in diluted EPS, signaling confidence in converting a much larger backlog and recent acquisitions into earnings. We will...

Why Black Stone Minerals Is In Focus After Its Latest Earnings Release Black Stone Minerals (BSM) is back on investors’ radar after releasing fourth quarter and full year 2025 results that highlighted higher revenue and net income, alongside fresh 2026 production guidance and detailed 2025 operating metrics. See our latest analysis for Black Stone Minerals. The earnings release and 2026 production guidance arrived after a steady run, with Black Stone Minerals’ share price showing an 11.77%...

Recent analyst upgrades on Palantir Technologies (PLTR), led by UBS and Rosenblatt, have refocused attention on the company’s role in artificial intelligence and data analytics, particularly following a sharp pullback in the share price. See our latest analysis for Palantir Technologies. Those upgrades and AI partnerships come after a sharp reset in sentiment, with a 30 day share price return of 6.41% and a 90 day share price return of 18.09% contrasted with a very large 3 year total...

Market reaction to new AI and photonics partnerships Tower Semiconductor (TSEM) has drawn fresh attention after a series of AI focused photonics partnerships, including Salience Labs, Xanadu, and Scintil Photonics, coincided with a 3.68% share price drop on 26 February. See our latest analysis for Tower Semiconductor. These AI and photonics deals come after a strong run for Tower Semiconductor, with a 90 day share price return of 11.63% and a 1 year total shareholder return of 193.81%...

If you are wondering whether Kaiser Aluminum's current share price lines up with its underlying worth, this article walks through the key signals you will want to weigh. The stock last closed at US$130.14, with returns of 0.9% over 7 days, 6.1% over 30 days, 8.2% year to date, 90.5% over 1 year, 74.0% over 3 years, and 36.6% over 5 years. This performance sets an important backdrop for any value check. Recent coverage around Kaiser Aluminum has focused on how investors view its role within...